Bakuchiol
CAS 10309-37-2
Bakuchiol (CAS 10309-37-2) is a Phase 1 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 17191.9674 nM | 50 | - |
| - | MIC | 24.133333333333333 ug.mL-1 | 15 | - |
| - | EC50 | 34504.57777777778 nM | 9 | - |
| - | IC50 | 25347.14285714286 nM | 7 | - |
| - | MIC | 397250 nM | 4 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BAKUCHIOL | 1368134 | SU | MTHSPL |
| bakuchiol | 1368134 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Bakuchiol used for in pharmaceutical contexts?
Bakuchiol (CAS 10309-37-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Bakuchiol?
No adverse-event association or SIDER side-effect rows are rendered for Bakuchiol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Bakuchiol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bakuchiol with EU status "permitted".
What clinical phase is Bakuchiol in?
Bakuchiol is rendered with ChEMBL max phase 1.